The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)

Overview

The main objective is to show the impact on the quality of life (QoL) for adults patients with advanced cancer managed in day hospital of integrated palliative care of cancer center (HDJ-SPI).

Full Title of Study: “The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 23, 2024

Interventions

  • Other: Hospital day care follow-up
    • Regular follow up every month in hospital day care

Arms, Groups and Cohorts

  • No Intervention: No hospital one day care
    • No hospital one day care
  • Other: Hospital one day care
    • Hospital one day care

Clinical Trial Outcome Measures

Primary Measures

  • Analyse impact of hospital day care in integrated palliative care department on quality of life of adult patients with advanced stage cancer
    • Time Frame: 12 months
    • Analyse impact of hospital day care in integrated palliative care department on quality of life of adult patients with advanced stage cancer Outcome shall be evaluated by assessing Survival without quality of life deterioration,measured by EORTC QLQ-C30 scale with monthly evaluation targeting three dimensions : global quality of life/ fatigue/ patient emotional state

Participating in This Clinical Trial

Inclusion Criteria

1. Patient ≥ 18 years old with advanced solid tumor 2. Addressed for the first time to the palliative care team according to current criteria (medico-psycho-social symptoms, progressive risks) 3. With or without anti-cancer treatment 4. With estimated life expectancy of more than 2 months and less than 12 months 5. Able to communicate in French and answer questionnaires 6. Affiliated with a social security system 7. Having signed informed consent, co-signed by the partner if designated by the patient Exclusion Criteria:

1. Patient with primitive brain tumor or malignant hemopathy 2. Severe psychopathological disorders 3. Pregnant patient or childbearing potential without effective method of birth control 4. Unable to be followed at the cancer center until death 5. Patient deprived of liberty or under guardianship -

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut Curie
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.